Dimopoulos, Meletios A.
Leleu, Xavier
Moreau, Philippe
Richardson, Paul G.
Liberati, Anna Marina
Harrison, Simon J.
Miles Prince, H.
Ocio, Enrique M.
Assadourian, Sylvie
Campana, Frank
Malinge, Laure
Sémiond, Dorothée
van de Velde, Helgi
Yong, Kwee
Funding for this research was provided by:
Sanofi (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
Article History
Received: 17 December 2019
Revised: 4 May 2020
Accepted: 11 May 2020
First Online: 23 May 2020
Compliance with ethical standards
:
: MAD: Consultancy: Bristol-Myers Squibb, Takeda, Amgen, Celgene, Janssen; Honoraria: Amgen, Celgene. SJH: Consultancy: Amgen, Sanofi, Celgene, Novartis, Janssen-Cilag, Karyopharm, Takeda, Haemalogix; Research funding: Celgene, Janssen-Cilag, Novartis; Patent: Novartis (panobinostat). HMP: Consultancy: Amgen, Sanofi, Celgene, Novartis; Research funding: Celgene, Bristol-Myers Squibb, Novartis. EMO: Research support: Amgen, Array BioPharma, Celgene, IDP-Pharma, Mundipharma; Honoraria: Janssen, Amgen, MSD, Asofarma, BMS, Takeda; Consultancy: Celgene, Janssen, Amgen, Sanofi, Secura Bio, Oncopeptides, Mundipharma, Takeda. SA, FC, LM, DS: Employment: Sanofi. HvdV: Employment: Sanofi; Stock Ownership: Sanofi. KY: Consultancy: Autolus; Honoraria: Amgen, Sanofi, Celgene, Takeda, Roche; Research funding: Sanofi, Celgene, Amgen.